The drugmaker’s revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Breast cancer patients were considering removing their ovaries until the maker of Zoladex 3.6mg said they would give the drug ...

A drug used to treat patients with life-threatening illnesses has received an important update after substantial community ...

Learn more AstraZeneca (AZN) and Daiichi Sankyo said Friday the European Commission approved Datroway as a first-line monotherapy for adults with unresectable or metastatic triple-negative breast ...

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall ...

AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of antibody-drug conjugates ...

AstraZeneca Plc reported higher-than-expected profit, buoyed by blockbuster cancer medicines, as focus turns to the company’s ...

AstraZeneca delivered solid core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year ...

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of ...

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

July 27 (Reuters) - AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President ...